Table 2.
Reproductive outcome in the SWV/Fnn mice following administration of 600 mg kg−1 of the valproyltaurine derivatives at GD 8.5
| Compound | Litters (N) | Implants (N) | Resorptions (N) (%) | Live births (N) | Malformed (N) (%) |
|---|---|---|---|---|---|
| VTA | 10 | 132 | 11 (8) | 121 | 0 |
| VTD | 9 | 108 | 27 (25)** | 81 | 0 |
| M-VTDa | 9 | 116 | 6 (5) | 110 | 1 (0.9) |
| DM-VTD | 9 | 130 | 45 (35)** | 85 | 14 (17)** |
| I-VTD | 8 | 104 | 23 (22)** | 81 | 6 (7)** |
| VPA (in H2O)b | 10 | 120 | 5 (4) | 115 | 59 (82)** |
| VPA (in CEL)a | 12 | 152 | 3d (2) | 119 | 89 (75)** |
| VPA (in H2O)a | 18 | 237 | 50b (21) | 181 | 109 (60)** |
| CEL controla | 10 | 120 | 5 (4) | 115 | 0 |
| CEL controla | 16 | 212 | 14f (7) | 196 | 0 |
| H2O controla | 12 | 152 | 3 (2) | 146 | 0 |
| VGDc | 15 | 178 | 1 (1) | 177 | 0 |
| VGAc | 7 | 97 | 6 (6) | 91 | 1 (1) |
| VPAc | 13 | 148 | 13 (9) | 135 | 99 (73)** |
| H2O controlc | 8 | 123 | 1 (1) | 122 | 0 |
a
Control for M-VTD treatment group
b
control for all other groups except M-VTD
c
VPA and H2O respective controls
d
Three stillborn fetuses
e
six stillborn fetuses
f
three stillborn fetuses
**
Significantly different from the respective vehicle-treated control group, P<0.05. VTA–valproyltaurine, VTD–valproyltaurinamide, M-VTD–N-methyl-valproyltaurinamide, DM-VTD–N,N-dimethyl-valproyltaurinamide, I-VTD–N-isopropyl valproyltaurinamide, VPA–valproic acid, CEL–cremophor EL.